Ascentage Pharma Group International (HKG:6855)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 12.51B -42.2% |
| Revenue (ttm) | 638.89M -41.5% |
| Net Income | -1.38B |
| EPS | -3.88 |
| Shares Out | 368.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,909,875 |
| Open | 34.80 |
| Previous Close | 34.80 |
| Day's Range | 33.90 - 36.18 |
| 52-Week Range | 30.00 - 95.35 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 86.81 (+155.85%) |
| Earnings Date | Aug 21, 2026 |
About HKG:6855
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2025, HKG:6855's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 6855 stock is "Strong Buy." The 12-month stock price target is $86.81, which is an increase of 155.85% from the latest price.
News
Ascentage Pharma assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Ascentage Pharma (AAPG) with an Outperform rating and $45 price target The firm notes Ascentage recently gave two oral presentations on olverembatinib at ASCO, as well…
Ascentage Pharma announces clinical updates from EHA2026
Ascentage Pharma (AAPG) announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: “Efficacy of Olveremb...
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en...
Ascentage Pharma initiated with a Buy at B. Riley
B. Riley initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $45 price target The company has two drugs approved and selling in China and those same two…
Ascentage Pharma Group International Transcript: Jefferies Global Healthcare Conference 2026
Two novel products are commercialized in China, with multiple global Phase III trials underway for lead assets targeting hematologic malignancies. Recent clinical data show strong efficacy and safety, and U.S. commercialization is planned for 2028, with NDA filings expected next year.
Ascentage Pharma presents data on olverembatinib
Ascentage Pharma (AAPG) Group announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib, as a second-line therapy in patients with chronic-phase ch...
Ascentage Pharma presents data from Phase 1b study of olverembatinib
Ascentage Pharma (AAPG) Group announced results from a Phase Ib study evaluating olverembatinib, the company’s core product, in combination with bispecific T-cell engager antibody blinatumomab in pati...
Ascentage Pharma presents first dataset of alrizomadlin
Ascentage Pharma (AAPG) announced that the Company presented its first dataset of alrizomadlin, an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination w...
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company eng...
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company eng...
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company eng...
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company eng...
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, integrated biopharmaceutical company engaged in the discov...
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, in...
Ascentage Pharma initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $40 price target The company two “de-risked, commercially validated” mechanisms in olverembatinib and Lisaftoclax, the...
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e...
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e...
Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript
Full Year 2025 Ascentage Pharma Group International Earnings Presentation Transcript
Ascentage Pharma Group International Earnings Call Transcript: H2 2025
Revenue grew 90% year-over-year to $82.1M, driven by olverembatinib and lisaftoclax launches, with strong commercial expansion and a $353.2M year-end cash balance. Multiple global phase III trials are advancing, with NDA filings targeted for 2027.
Ascentage Pharma Group International Slides: H2 2025
Ascentage Pharma Group International has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Ascentage Pharma Group International Annual report: H2 2025
Ascentage Pharma Group International has published its H2 2025 annual report on March 26, 2026.
Ascentage Pharma Group International Earnings release: H2 2025
Ascentage Pharma Group International released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Ascentage Pharma Group International Annual report: H2 2025
Ascentage Pharma Group International has published its H2 2025 annual report on March 26, 2026.
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” the “C...
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e...